For the first time in history, there is now hope for treating neurological disorders that had previously been considered untreatable. The remarkable confluence of events that has heralded this is the focus of Neurotherapeutics in the Era of Translational Medicine. This anthology, written by many of the prominent scientists and researchers in the field of biotechnology, recounts the breathtaking advances that are revolutionizing treatment for disorders such as amyotrophic lateral sclerosis¿, spinal muscular atrophy, multiple sclerosis, Parkinson's disease, myasthenia gravis, migraine, and glioblastoma. The "story behind the story" of these translational efforts is told, with authors depicting the ups and downs encountered on the path of their drug discovery and development effort. In parallel with this path, advances in identifying novel biomarkers and disease models are summarized, as are contemporary issues focusing on clinical trial design, bioethics, innovative funding strategies, and collaborations between government and academia in an effort to facilitate breakthrough treatments. The book is written by members of the biotech and pharmaceutical ecosystem for those who belong to it and aspire to become part of it.
- Comprehensive review on the progress of translational research in neurotherapeutics for neurologic disorders
- Discusses important issues in clinical trials such as design and ethical issues
- Written for neuroscientists, neurologists and pharmacologists
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
ISBN-13
978-0-12-817274-2 (9780128172742)
Schweitzer Klassifikation
1. Development of a molecular therapy for the SOD1 familial variant of ALS2. Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy3. Translating molecular therapies for spinal muscular atrophy4. From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy5. A novel treatment for Parkinson's disease and ALS: Combined celland gene therapies6. Parkinson's disease: Genetic-driven therapeutic approaches7. Neural stem cell-mediated brain tumor therapy8. Advances in migraine therapeutics: The role of calcitoningene-related peptide9. The impact of translational research on the development of therapeuticagents for multiple sclerosis10. Advances in treating myasthenia gravis 11. The endocannabinoid system as a target for the treatmentof neurological disorders12. Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders13. 3D Alzheimer's disease in a dish: Implications for drug discovery14. Improving clinical trial efficiency with machine learning modelsof disease progression15. Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development 16. Repurposing FDA-approved pharmaceuticals: The developmentof Nuedexta17. Bioethics in the era of translational medicine18. Government efforts to promote the development of neurotherapeutics for the treatment of neurological diseases19. Innovative funding models for neurotherapeutics
